Recombinant Human IL-3 Protein，His

Interleukin-3 (IL-3) is a cytokine that plays a crucial role in hematopoiesis, the process of forming blood cellular components. It is produced by activated T cells and is essential for the growth and differentiation of various hematopoietic lineages, including myeloid, erythroid, and megakaryocytic cells. Research into IL-3 has gained significant attention due to its potential implications in various clinical settings, such as hematological disorders and immunotherapy. Recombinant IL-3 (rIL-3) has been developed for therapeutic applications, aiming to enhance hematopoietic recovery following chemotherapy or bone marrow transplant. Studies have shown that rIL-3 can stimulate the proliferation of progenitor cells, leading to improved blood cell counts. Furthermore, it has been explored in combination therapies to increase the efficacy of certain cancer treatments. Understanding the molecular mechanisms underlying IL-3 signaling pathways is vital for harnessing its full therapeutic potential. Additionally, IL-3's role in the immune response makes it a candidate for investigating immune-related diseases, where modulation of IL-3 levels could influence disease outcomes. Overall, continued research on IL-3 and its recombinant form offers promising avenues for novel treatments in oncology and immunology, highlighting its significance in both basic and applied biomedical research.